Glenn Yiu1, R Joel Welch2, Yinwen Wang2, Zhe Wang2, Pin-Wen Wang3, Zdenka Haskova3. 1. Department of Ophthalmology and Vision Science, University of California, Davis, Sacramento, California. Electronic address: gyiu@ucdavis.edu. 2. Department of Ophthalmology and Vision Science, University of California, Davis, Sacramento, California. 3. Genentech, Inc, San Francisco, California.
Abstract
PURPOSE: To evaluate spectral-domain (SD)-OCT features associated with baseline vision and visual outcomes in the prospective, multicenter Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema following Retinal Vein Occlusion (SHORE). DESIGN: Post hoc analysis of prospective clinical trial data. PARTICIPANTS: Two hundred two participants in the 15-month, phase 4 SHORE study comparing monthly versus pro re nata ranibizumab after 7 monthly doses in eyes with retinal vein occlusion (RVO) with macular edema. METHODS: Baseline SD-OCT images were assessed for (1) central subfield thickness (CST); (2) presence of vitreomacular adhesion, vitreomacular traction, or epiretinal membrane; (3) presence, location, and amount of intraretinal fluid or subretinal fluid (SRF); (4) presence, location, and amount of hyperreflective foci (HF); (5) disorganization of retinal inner layers (DRIL); and (6) disruption of external limiting membrane (ELM), ellipsoid zone (EZ), and interdigitation zone (IZ). Univariate and multivariate regression analyses were performed to evaluate the association of these features with baseline best-corrected visual acuity (BCVA) and change in BCVA after 7 monthly ranibizumab injections. MAIN OUTCOME MEASURES: Association of SD-OCT features with baseline BCVA and change in BCVA after 7 monthly ranibizumab injections. RESULTS: Before therapy, worse baseline BCVA was associated with ERM presence (P = 0.0045), thicker SRF (P = 0.0006), larger intraretinal cysts (P = 0.0015), and higher percentage of DRIL (P < 0.0001), percentage of ELM disruption (P < 0.0001), percentage of EZ disruption (P = 0.0003), and percentage of IZ disruption (P = 0.0018). In multivariate models, only percentage of ELM disruption independently impacted baseline BCVA (P < 0.0001). After 7 monthly ranibizumab injections, mean BCVA improved by 18.3±12.6 Early Treatment Diabetic Retinopathy Study letters in treated eyes. The only factors independently associated with BCVA gain after 7 monthly ranibizumab treatments were younger age (P < 0.0001) and worse baseline BCVA (P < 0.0001). CONCLUSIONS: Although SD-OCT features may be associated with presenting vision in eyes with macular edema and RVO, most eyes treated with ranibizumab achieve substantial vision gains, and only older age and better baseline BCVA limited visual improvements.
PURPOSE: To evaluate spectral-domain (SD)-OCT features associated with baseline vision and visual outcomes in the prospective, multicenter Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema following Retinal Vein Occlusion (SHORE). DESIGN: Post hoc analysis of prospective clinical trial data. PARTICIPANTS: Two hundred two participants in the 15-month, phase 4 SHORE study comparing monthly versus pro re nataranibizumab after 7 monthly doses in eyes with retinal vein occlusion (RVO) with macular edema. METHODS: Baseline SD-OCT images were assessed for (1) central subfield thickness (CST); (2) presence of vitreomacular adhesion, vitreomacular traction, or epiretinal membrane; (3) presence, location, and amount of intraretinal fluid or subretinal fluid (SRF); (4) presence, location, and amount of hyperreflective foci (HF); (5) disorganization of retinal inner layers (DRIL); and (6) disruption of external limiting membrane (ELM), ellipsoid zone (EZ), and interdigitation zone (IZ). Univariate and multivariate regression analyses were performed to evaluate the association of these features with baseline best-corrected visual acuity (BCVA) and change in BCVA after 7 monthly ranibizumab injections. MAIN OUTCOME MEASURES: Association of SD-OCT features with baseline BCVA and change in BCVA after 7 monthly ranibizumab injections. RESULTS: Before therapy, worse baseline BCVA was associated with ERM presence (P = 0.0045), thicker SRF (P = 0.0006), larger intraretinal cysts (P = 0.0015), and higher percentage of DRIL (P < 0.0001), percentage of ELM disruption (P < 0.0001), percentage of EZ disruption (P = 0.0003), and percentage of IZ disruption (P = 0.0018). In multivariate models, only percentage of ELM disruption independently impacted baseline BCVA (P < 0.0001). After 7 monthly ranibizumab injections, mean BCVA improved by 18.3±12.6 Early Treatment Diabetic Retinopathy Study letters in treated eyes. The only factors independently associated with BCVA gain after 7 monthly ranibizumab treatments were younger age (P < 0.0001) and worse baseline BCVA (P < 0.0001). CONCLUSIONS: Although SD-OCT features may be associated with presenting vision in eyes with macular edema and RVO, most eyes treated with ranibizumab achieve substantial vision gains, and only older age and better baseline BCVA limited visual improvements.
Authors: David M Brown; Peter A Campochiaro; Rishi P Singh; Zhengrong Li; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Roman G Rubio; Wendy Yee Murahashi Journal: Ophthalmology Date: 2010-04-09 Impact factor: 12.079
Authors: Peter A Campochiaro; Jeffrey S Heier; Leonard Feiner; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Wendy Yee Murahashi; Roman G Rubio Journal: Ophthalmology Date: 2010-04-15 Impact factor: 12.079
Authors: Glenn Yiu; Zhe Wang; Christian Munevar; Eric Tieu; Bradley Shibata; Brittany Wong; David Cunefare; Sina Farsiu; Jeffrey Roberts; Sara M Thomasy Journal: Exp Eye Res Date: 2018-01-17 Impact factor: 3.467
Authors: Ute E K Wolf-Schnurrbusch; Ramzi Ghanem; Simon P Rothenbuehler; Volker Enzmann; Carsten Framme; Sebastian Wolf Journal: Invest Ophthalmol Vis Sci Date: 2011-05-18 Impact factor: 4.799
Authors: Alex S Willoughby; Vivian S Vuong; David Cunefare; Sina Farsiu; Glenn Noronha; Ronald P Danis; Glenn Yiu Journal: Am J Ophthalmol Date: 2017-12-02 Impact factor: 5.258
Authors: Tyler Etheridge; Barbara Blodi; Neal Oden; Paul Van Veldhuisen; Ingrid U Scott; Michael S Ip; Mihai Mititelu; Amitha Domalpally Journal: Ophthalmol Retina Date: 2020-12-26
Authors: Tyler Etheridge; Ellen T A Dobson; Marcel Wiedenmann; Neal Oden; Paul VanVeldhuisen; Ingrid U Scott; Michael S Ip; Kevin W Eliceiri; Barbara A Blodi; Amitha Domalpally Journal: Transl Vis Sci Technol Date: 2021-03-01 Impact factor: 3.283